Analyst Thursdays: Mizuho Senior Biotech Analyst Graig Suvannavejh shares his take on three key biotech trials that are scheduled to read out soon, and one that recently happened

Feb 12
1 min read

He discusses upcoming readouts for IDEAYA Biosciences, Ocular Therapeutix (how it might affect EyePoint), and Palvella Therapeutics. Plus, his take on the recent Corvus atopic dermatitis data.

https://vimeo.com/1164522309

Chapters

IDEAYA Biosciences - 0:46

EyePoint / Ocular - 3:45

Palvella - 7:43

Corvus - 12:30

Recent Posts

See All

The Zayed Centre for Research into Rare Disease in Children at Great Ormond Street Hospital (GOSH) in London has already been at the cutting edge of new technologies since it opened in 2019

BIO 2026: Sofinnova Investments' Managing Partner Jim Healy shares his (optimistic) take on the current state of biotech and the venture side of it

EHA 2026: H.C. Wainwright Senior Biotech Analyst Mitchell Kapoor previews key EHA data from Legend and Incyte, and shares catalysts he is watching for after the conference

Analyst Thursdays: Mizuho Senior Biotech Analyst Graig Suvannavejh shares his take on three key biotech trials that are scheduled to read out soon, and one that recently happened

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight